Atrial fibrillation in hypertrophic cardiomyopathy: modern aspects of epidemiology, risk factors, pathogenesis and medication-assisted treatment

Cover Page

Cite item

Full Text

Abstract

Atrial fibrillation (AF) is a particularly important arrhythmia in hypertrophic cardiomyopathy (HCM). This article describes the epidemiology of AF within the HCM population and analyses risk factors for the development of AF. The possible relation between the development of atrial fibrillation (AF) and insulin resistance in patients with HCM is also discussed. Here, we also review the outcomes associated with AF in HCM population and pharmacologic treatment strategies in this patient group

About the authors

A. A Streltsova

V.A.Almazov National Medical Research Center

Email: anikas1985@gmail.com
врач ультразвуковой диагностики 197341, Russian Federation, Saint Petersburg, ul. Akkuratova, d. 2

A. Ya Gudkova

V.A.Almazov National Medical Research Center; I.P.Pavlov First Saint Petersburg State Medical University

Email: alexagood-1954@mail.ru
д-р мед. наук, зав. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний, проф. каф. факультетской терапии 197341, Russian Federation, Saint Petersburg, ul. Akkuratova, d. 2; 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8

A. A Kostareva

V.A.Almazov National Medical Research Center; I.P.Pavlov First Saint Petersburg State Medical University

Email: akostareva@hotmail.com
канд. мед. наук, доц. каф. факультетской терапии; дир. Института молекулярной биологии и генетики 197341, Russian Federation, Saint Petersburg, ul. Akkuratova, d. 2; 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8

References

  1. Authors/Task Force members, Elliott P.M, Anastasakis A, Borger M.A et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733-79. doi: 10.1093/eurheartj/ehu284
  2. Semsarian C, Ingles J, Maron M.S, Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65 (12): 1249-54. doi: 10.1016/j.jacc.2015. 01.019
  3. Maron B.J, Maron M.S, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60 (8): 705-15. doi: 10.1016/j.jacc.2012.02. 068
  4. Lopes L.R, Zekavati A, Syrris P et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013; 50 (4): 228-39. doi: 10.1136/jmedgenet-2012-101270
  5. Kassem H.Sh, Azer R.S, Saber-Ayad M et al. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J Cardiovasc Translat Res 2013; 6 (1): 65-80. doi: 10.1007/s12265-012-9425-0
  6. Van Driest S.L, Ommen S.R, Tajik A.J et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings 2005; 80 (6): 739-44. doi: 10.4065/80.6.739
  7. Brito D, Miltenberger-Miltenyi G, Vale Pereira S et al. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol 2012; 31 (9): 577-87. doi: 10.1016/j.repc.2011.12.020
  8. Morita H, Rehm H.L, Menesses A et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358 (18): 1899-908. doi: 10.1056/NEJMoa075463
  9. Alfares A.A, Kelly M.A, McDermott G et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015; 17 (11): 880-8. doi: 10.1038/gim.2014.205.
  10. Hodatsu A, Konno T, Hayashi K et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol - Heart and Circulatory Physiology 2014; 307 (11): H1594-H1604. doi: 10.1152/ajpheart.00637.2013
  11. Girolami F, Ho C.Y, Semsarian C et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010; 55 (14): 1444-53. doi: 10.1016/j.jacc.2009.11.062
  12. Li L, Bainbridge M.N, Tan Y et al. A potential oligogenic etiology of hypertrophic cardiomyopathy: a classic single-gene disorder. Circulation Res 2017; 120: 1084-90. doi: 10.1161/CIRCRESAHA.116.310559
  13. Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. doi: 10.1016/j.cjca.2017.07.007
  14. Marian A.J, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Res 2017; 121 (7): 749-70. doi: 10.1161/CIRCRESAHA.117.311059
  15. Eriksson M.J, Sonnenberg B, Woo A et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39 (4): 638-45. doi: 10.1016/S0735-1097(01)01778-8
  16. Binder J, Attenhofer Jost C.H, Klarich K.W et al. Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. J Am Soc Echocardiogr 2011; 24 (7): 775-81. doi: 10.1016/j.echo.2011.03.002
  17. D’Amato R, Tomberli B, Castelli G et al. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol 2013; 112 (8): 1190-6. doi: 10.1016/j.amjcard.2013.06.018
  18. Guttmann O.P, Rahman M.S, O'Mahony C et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100 (6): 465-72. doi: 10.1136/heartjnl-2013-304276
  19. Rowin E.J, Hausvater A, Link M. et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017. doi: 10.1161/CIRCULATIONAHA.117.029267
  20. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm A.J, Kirchhof P, Lip G.Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369-29. doi: 10.1093/eurheartj/ehq278
  21. Lloyd-Jones D.M, Wang T.J, Leip E.P et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110 (9): 1042-6. doi: 10.1161/01.CIR. 0000140263.20897.42
  22. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38): 2893-962. doi: 10.1093/eurheartj/ehw210
  23. Camm C.F, Camm A.J. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythm and Electrophysiol Rev 2017; 6 (2): 63-8. doi: 10.15420/aer.2017.4.2
  24. Крылова Н.С., Демкина А.Е., Хашиева Ф.М. и др. Фибрилляция и трепетание предсердий у больных с гипертрофической кардиомиопатией. Рос. кардиол. журн. 2015; 5: 64-70. doi: 10.15829/1560-4071-2015-5-64-70.
  25. Gruver E.J, Fatkin D, Dodds G.A et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 1999; 83 (12A): 13H-18H. doi: 10.1016/s0002-9149(99)00251-9
  26. Ogimoto A, Hamada M, Nakura J et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47 (4): 184-9. doi: 10.1007/s100380200021
  27. Spirito P, Autore C, Formisano F et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113 (9): 1550-5. doi: 10.1016/j.amjcard.2014.01.435
  28. Tani T, Tanabe K, Ono M et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17 (6): 644-8. doi: 10.1016/j.echo.2004.02.010
  29. Olivotto I, Cecchi F, Casey S.A et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104 (21): 2517-24. doi: 10.1161/hc4601.097997
  30. Losi M.A, Betocchi S, Aversa M et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 94 (1): 895-900. doi: 10.1016/j.amjcard.2004.06.024
  31. Siontis K.C, Geske J.B, Ong K et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Association 2014; 3 (3): e001002. doi: 10.1161/JAHA.114.001002
  32. Doesch C, Lossnitzer D, Rudic B et al. Right ventricular and right atrial involvement can predict atrial fibrillation in patients with hypertrophic cardiomyopathy? Int J Med Sci 2016; 13 (1): 1-7. doi: 10.7150/ijms.13530
  33. Autore C, Bernabo P, Barilla C.S et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45 (7): 1076-80. doi: 10.1016/j.jacc.2004.12.067
  34. Maron B.J, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102 (8): 858-64. doi: 10.1161/01.CIR.102.8.858
  35. Yang W.I, Shim C.Y, Kim Y.J et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22 (12): 1338-43. doi: 10.1016/j.echo.2009.09.016
  36. Desai M.Y, Bhonsale A, Smedira N.G et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 2013; 128 (3): 209-16. doi: 10.1161/CIRCULATIONAHA.112.000849
  37. Ohe T. Results from the Kochi RYOMA Study. Atrial fibrillation is a major risk of morbidity in patients with hypertrophic cardiomyopathy. Сirculation J 2009; 73 (9): 1589-90. doi: 10.1253/circj.CJ-09-0433
  38. Tian T, Wang Y, Sun K et al. Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy. Cardiology 2013; 126 (4): 258-64. doi: 10.1159/000354953
  39. Ash-Bernal R, Peterson L.R. The cardiometabolic syndrome and cardiovascular disease. J Cardiometabolic Syndrome. 2006; 1 (1): 25-8. doi: 10.1111/j.0197-3118.2006.05452.x
  40. Umetani K, Kodama Y, Nakamura T et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circulation J 2007; 71 (2): 252-5. doi: 10.1253/circj.71.252
  41. Watanabe H, Tanabe N, Watanabe T et al. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata preventive medicine study. Circulation 2008; 117 (10): 1255-60. doi: 10.1161/CIRCULATIONAHA.107.744466
  42. ВНОК. Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваск. терапия и профилактика. 2007; 6 (6), Прил. 2.
  43. Баранова Е.И., Листопад О.В., Соболева А.В., Яцук Д.И. Гипертоническая болезнь и другие причины фибрилляции предсердий у пациентов, госпитализированных в терапевтическую клинику. Кардиология: новости, мнения, обучение. 2013; 1: 85-92.
  44. Nguyen J.T, Benditt D.G. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 2008; 117 (10): 1249-51. doi: 10.1161/CIRCULATIONAHA.107.760777
  45. Russo C, Jin Z, Homma S et al. Effect of Obesity and Overweight on Left Ventricular Diastolic Function: a Community-based Study in an Elderly Cohort. J Am Col Cardiol 2011; 57 (12): 1368-74. doi: 10.1016/j.jacc.2010.10.042
  46. Ruige J.B, Assendelft W.J, Dekker J.M et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97 (10): 996-1001. doi: 10.1161/01.CIR.97.10.996
  47. Savage D.B, Petersen K.F, Shulman G.I. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828-33. doi: 10.1161/01.HYP. 0000163475.04421.e4
  48. Chung M.K, Martin D.O, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104 (24): 2886-91. doi: 10.1161/hc4901.101760
  49. Mihm M.J, Yu F, Carnes C.A et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104 (2): 174-80. doi: 10.1161/01.CIR.104.2.174
  50. Murakami K, Shigematsu Y, Hamada M, Higaki J. Insulin resistance in patients with hypertrophic cardiomyopathy. Circulation J 2004; 68 (7): 650-5. doi: 10.1253/circj.68.650
  51. Harano Y, Suzuki M, Koyama Y et al. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications 2002; 16 (1): 19-23. doi: 10.1016/S1056-8727(01)00192-1
  52. Shigematsu Y, Hamada M, Nagai T et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011; 58 (1): 18-25. doi: 10.1016/j.jjcc.2011.03.001
  53. Gersh B.J, Maron B.J, Bonow R.O et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783-831. doi: 10.1161/CIR.0b013e318223e2bd
  54. Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. doi: 10.1016/j.cjca.2017.07.007
  55. Moore J.C, Trager L, Anzia L.E et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing ClinElectrophysiol 2018. doi: 10.1111/pace.13310.
  56. Ammirati E, Contri R, Coppini R et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Failure 2016; 18 (9): 1106-18. doi: 10.1002/ejhf.541
  57. Quintana E, Cox J.L. Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothoracic Surg 2017; 6 (4): 386-93. doi: 10.21037/acs.2017.05.08.
  58. January C.T, Wann L.S, A.J.S Calkins H et al.; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-267. doi: 10.1161/CIR.0000000000000041
  59. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circulation J 2016; 80: 753-74. doi: 10.1253/circj.CJ-66-0122
  60. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circulation J 2014; 78: 1997-2021. doi: 10.1253/circj.CJ-66-0092
  61. Лебедев Д.С., Михайлов Е.Н., Гуреев С.В. и др. Катетерная аблация хронической фибрилляции предсердий у пациента с гипертрофической кардиомиопатией. Вестн. аритмологии. 2008; 51: 72-4.
  62. Ikenaga H, Nakano Y, Oda N et al. Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure. J Arrhythmia 2017; 33 (4): 256-61. doi: 10.1016/j.joa.2016.08.006
  63. Providencia R, Elliott P, Patel K et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart (British Cardiac Society) 2016; 102 (19): 1533-43. doi: 10.1136/heartjnl-2016-309406
  64. Maagh P, Plehn G, Christoph A et al. Impact of Cryoballoon Ablation in Hypertrophic Cardiomyopathy-related Heart Failure due to Paroxysmal Atrial Fibrillation. A Comparative Case Series. Int J Med Sci 2016; 13 (9): 664-72. doi: 10.7150/ijms.16181
  65. Бокерия Л.А., Бокерия О.Л., Климчук И.Я., Санакоев М.К. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий. Анналы аритмологии. 2016; 13 (4): 216-21. doi: 10.15275/annaritmol.2016.4.4

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies